After Scioderm, Robert Ryan enters into second act

Robert Ryan will give it another go. Ryan is the former co-founder and chief executive of Scioderm, Inc., a drug developer acquired in a deal that could ultimately be worth nearly $1 billion. At the end of 2015, Ryan left the company and now will launch a new drug development company not unlike his former one. Scioderm, which was acquired by New Jersey-based Amicus Therapeutics, is developing a drug called Zorblisa that would treat Epidermolysis Bullosa (EB), a rare skin disease that affects infants…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news